Pretreatment Pregnancy Testing Under iPLEDGE in 2026: Pharmacy and Prescriber Questions for Adult Acne Patients

In 2026, adult acne patients who can become pregnant must have a screening pregnancy test and a negative confirmatory test before the first isotretinoin dose. Prescribers order and record both tests, and pharmacies must confirm authorization before dispensing.

iPLEDGE is the FDA-required safety program for isotretinoin to reduce the risk of exposure during pregnancy. The pretreatment process applies to adults considered for isotretinoin for severe recalcitrant nodular acne that has not responded to conventional therapy. According to National Library of Medicine labeling, the drug is indicated for nonpregnant patients age 12 and older with multiple 5-mm or greater inflammatory nodules National Library of Medicine drug labeling.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Who needs pretreatment testing?
How do prescribers time the two tests?
What changes in August 2026?
What will the pharmacy check?
How can adults avoid treatment interruption?

Who needs pretreatment testing?

Patients who can become pregnant need both the screening test and the confirmatory test. Patients who cannot become pregnant follow prescriber and enrollment steps without test-based authorization.

All pretreatment tests must be completed in a medical setting such as an office, clinic, or laboratory. Home tests do not satisfy the pretreatment requirement. According to the FDA medical organizations letter, the prescriber obtains a screening test when deciding to prescribe and a negative confirmatory test before the first dose FDA medical organizations letter.

How do prescribers time the two tests?

The FDA briefing describes a 30-day period after enrollment, with the second confirmatory test timed during the first five days of the menstrual cycle immediately before therapy. That timing is intended to increase assurance that the patient is not pregnant at the start.

Prescribers also document contraception. The iPLEDGE Prescriber Guide states that patients who can become pregnant must use continuous abstinence or two accepted contraception forms together for one month before, during, and one month after treatment. For an adult visit, the practical sequence is:.

complete iPLEDGE enrollment and contraception counseling
complete the screening pregnancy test when isotretinoin is first considered
complete the confirmatory test in the specified cycle window before the first dose

What changes in August 2026?

According to Drugs.com reporting on the FDA approval, FDA approved iPLEDGE modifications on Feb. 9, 2026, effective Aug. 9, 2026 after 180 days Drugs.com report on the FDA approval. The change removes the requirement for CLIA-certified laboratory pregnancy testing.

Pretreatment testing must still occur in a medical setting. Home tests are permitted during and after treatment under the modified approach. Adults should ask whether the visit site uses office, clinic, or laboratory testing. The location still matters for the first two tests, even without CLIA certification.

What will the pharmacy check?

Pharmacies may dispense only with an iPLEDGE Risk Management Authorization. According to FDA REMS counseling materials, the prescriber enters the negative test and contraception information, the patient answers comprehension questions with matching entries, and pickup must occur within seven days of the pregnancy-test date FDA contraception counseling guide. Bring identification, confirm that prescriber and patient entries match, and plan pickup promptly.

A mismatch or late pickup can prevent dispensing. Adults balancing work should coordinate the test date, authorization, and pharmacy hours in advance. A test early in the seven-day period leaves more time for pickup.

How can adults avoid treatment interruption?

A missed seven-day pickup window no longer triggers the prior extended lockout. According to the Medaptly summary of the 2026 FDA changes, elimination of the 19-day lockout lets a patient repeat pregnancy testing and requalify promptly. That relief matters for adults with inflexible schedules, limited pharmacy access, or authorization delays.

Repeat testing still must meet iPLEDGE requirements. If the window is missed, contact the prescriber promptly about repeat testing and reauthorization. Ask for a test appointment and pharmacy plan in the same week to restart without added delay.